Adjuvant braf-mek inhibitors versus anti pd-1 therapy in stage iii melanoma: a propensity-matched outcome analysis

HIGHLIGHTS

• who: Melissa M. De Meza et al. from the Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg, AA Leiden, The Netherlands Department of Biomedical Data Sciences, Leiden University Medical Center, Albinusdreef have published the Article: Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis, in the Journal: Cancers 2023, 409 of 30/Dec/2022
• what: For this study stage III V600 mutant cutaneous melanoma patients treated with adjuvant BRAF/MEKinhibition or anti-PD-1 were identified from the Dutch Melanoma Treatment Registry. The authors report a . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.